Patent ID: 7919087

Claim:
A method for treating a CD74-positive multiple myeloma comprising administering to a subject with a CD74-positive multiple myeloma a therapeutic composition comprising at least one humanized or chimeric anti-CD74 antibody or antigen-binding fragment thereof comprising the light chain variable region complementarity-determining region (CDR) sequences CDR1 (RSSQSLVHRNGNTYLH; SEQ ID NO:16), CDR2 (TVSNRFS; SEQ ID NO:17), and CDR3 (SQSSHVPPT; SEQ ID NO:18) and the heavy chain variable region CDR sequences CDR1 (NYGVN; SEQ ID NO:19), CDR2 (WINPNTGEPTFDDDFKG; SEQ ID NO:20), and CDR3 (SRGKNEAWFAY; SEQ ID NO:21), and wherein said anti-CD74 antibody or fragment thereof is a naked antibody or fragment thereof.